260809-26-5

Basic information

• Product Name: (4-BROMO-BENZYL)-METHYL-CARBAMIC ACID TERT-BUTYL ESTER
• Synonyms: N-Boc-N-Methyl-4-broMobenzylaMine;tert-butyl (4-bromobenzyl)methylcarbamate;(4-BROMO-BENZYL)-METHYL-CARBAMIC ACID TERT-BUTYL ESTER
• CAS NO: 260809-26-5
• Molecular Formula: C₁₃H₁₈BrNO₂
• Molecular Weight: 300.2
• Mol File: 260809-26-5.mol

Chemical Properties

• Boiling Point: 354.5±21.0 °C(Predicted)
• Appearance: /
• Density: 1.295±0.06 g/cm3(Predicted)
• PKA: -1.48±0.70(Predicted)
• CAS DataBase Reference: (4-BROMO-BENZYL)-METHYL-CARBAMIC ACID TERT-BUTYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: (4-BROMO-BENZYL)-METHYL-CARBAMIC ACID TERT-BUTYL ESTER(260809-26-5)
• EPA Substance Registry System: (4-BROMO-BENZYL)-METHYL-CARBAMIC ACID TERT-BUTYL ESTER(260809-26-5)

Safety Data

• Hazardous Substances Data: 260809-26-5(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
(4-BROMO-BENZYL)-METHYL-CARBAMIC ACID TERT-BUTYL ESTER is used as a reagent in organic synthesis for its ability to react with a variety of other compounds, enabling the formation of new organic molecules.
Used in Pharmaceutical Research:
In the pharmaceutical industry, (4-BROMO-BENZYL)-METHYL-CARBAMIC ACID TERT-BUTYL ESTER is used as a research compound to aid in the development and understanding of new drugs and their mechanisms of action.
It is important to handle (4-BROMO-BENZYL)-METHYL-CARBAMIC ACID TERT-BUTYL ESTER with care, as it may pose hazards if mishandled or improperly disposed of.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 26177-44-6 4-bromobenzylamine hydrochloride 
• 68819-84-1 tert-butyl N-(4-bromobenzyl)carbamate 
• 74-88-4 methyl iodide 
• 699-03-6 N-methyl-4-bromobenzylamine 
• 1122-91-4 4-bromo-benzaldehyde 

Downstream Products

• 936728-17-5 tert-butyl methyl(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)carbamate 

Relevant articles and documents

Copper-Mediated Radiosynthesis of [18F]Rucaparib

The poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib is used in the clinic to treat BRCA-mutated cancers. Herein, we report two strategies to access the 18F-isotopologue of rucaparib by applying a copper-mediated nucleophilic 18F-fluorodeboronation. The most successful approach features an aldehydic boronic ester precursor that is subjected to reductive amination post-18F-labeling and affords [18F]rucaparib with an activity yield of 11% ± 3% (n = 3) and a molar activity (Am) up to 30 GBq/μmol. Preliminary in vitro studies are presented.

SUBSTITUTED BICYCLE HETEROCYCLIC DERIVATIVES USEFUL AS ROMK CHANNEL INHIBITORS

Disclosed are compounds of Formula (I) or a salt thereof, wherein R1 is (II) or (III); each W is independently NR1b or O; Z is a bond or CHR1d; and R1, R2, Rd, R3, L1, L2, R1a, R1b, R1c, and n are define herein. Also disclosed are methods of using such compounds as inhibitors of ROMK, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating cardiovascular diseases.

A fragment merging approach towards the development of small molecule inhibitors of Mycobacterium tuberculosis EthR for use as ethionamide boosters

With the ever-increasing instances of resistance to frontline TB drugs there is the need to develop novel strategies to fight the worldwide TB epidemic. Boosting the effect of the existing second-line antibiotic ethionamide by inhibiting the mycobacterial

Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.